Board and Management

The Board and Management of VivaZome Therapeutics – Ian Nisbet, Craig Newton and Xenia Sango  – have over 75 years of combined biotech and pharmaceutical experience with activity in Australia, Asia, North America, Europe, the Middle East and Central America.

Ian Nisbet – Chairperson 

Ian Nisbet has over 30 years experience in biologicals and biotech.Ian was previously CEO/MD of Xenome Ltd and Meditech Research Ltd and has held senior management positions at Millennium Pharmaceuticals Inc in US, ChemGenex Pharmaceuticals Ltd and CSL Ltd. Ian is currently Chairman at VivoPharm Pty Ltd, a director at 4 biotechs and a Corporate advisor at Cartherics, a cell therapy company.

Craig Newton – Executive Director and CEO

Craig Newton is a Business Executive with 30 years’ experience in the Healthcare industry, notably in the Medical Device, Pharmaceutical and Biotech sectors, with activity in Australasia, Asia and Europe. His tertiary and post-graduate qualifications cover Science and Business, including an executive program at Babson College, Boston. Experience encompasses diverse therapeutic areas, including cardiovascular disease oncology, haematology, cell therapies, fertility and immunology. Organizations have included CSL, Serono UK, CSIRO, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals, with roles of “Chief Operating Officer”, “Sales and Marketing Director” and “Business Unit Manager”. At Serono in the UK, as Head of the Reproductive Health Division, he ran a $50m business, growing market share in the face of intense low-cost competition. As Head of Sales and Marketing at Bio Nova International, he grew the international sales and industry profile leading to the company’s successful acquisition by a major US player.

Xenia Sango – Clinical and Regulatory Consultant

Xenia Sango is a highly experienced healthcare executive and independent consultant with over 25 years in senior clinical, regulatory and international commercialisation roles. Xenia’s  positions at CSL Limited included Senior Director of Influenza Commercial Operations; Director of International Registrations, and Head of Regulatory Affairs. Xenia’s experience included registration of the novel therapeutic rec Factor VIII in Australia and New Zealand, setting up CSL’s  global regulatory function,  and launching  CSL’s Fluvax in US and Europe, including establishing subsidiaries in USA and Germany.  In Japan, Xenia set up commercial and manufacturing operations for CSL. As Business Development Manager Research at Epworth HealthCare, Xenia expanded the research business, managed the Clinical Research Unit and set up Phase 1b capability.